METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
AssigneeImmunoGen, Inc.
InventorsSharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
Life of this patent
Estimating the term…
Abstract
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
Claims24
A composition of matter comprising an anti-ErbB2 antibody covalently linked to a maytansinoid by succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), wherein the anti-ErbB2 antibody is a humanized or human antibody.
A composition comprising huMAb4D5-8 (HERCEPTIN®) conjugated to DM1 by succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), wherein DM1 has the structure
An immunoconjugate comprising an anti-ErbB2 antibody conjugated to a maytansinoid, wherein the antibody is huMAb4D5-8.
Dependencies are inferred from the claim text.